Progress of poly (ADP-ribose) polymerase inhibitor resistance in ovarian cancer
10.3760/cma.j.cn115355-20240418-00188
- VernacularTitle:聚腺苷二磷酸核糖聚合酶抑制剂耐药在卵巢癌中的研究进展
- Author:
Lei GAO
1
;
Hongwei ZHAO
Author Information
1. 山西医科大学第二临床医学院，太原 030001
- Keywords:
Ovarian neoplasms;
Poly (ADP-ribose) polymerase inhibitors;
Drug tolerance
- From:
Cancer Research and Clinic
2024;36(9):705-708
- CountryChina
- Language:Chinese
-
Abstract:
Poly (ADP-ribose) polymerase (PARP) inhibitors have significantly improved the survival of patients with advanced or recurrent ovarian cancer. Despite the remarkable efficacy, resistance to PARP inhibitors has been reported. This article reviews the mechanism of PARP inhibitors to exert their therapeutic effect, the precise molecular mechanisms of primary and secondary resistance to PARP inhibitors, as well as the corresponding therapeutic measures to overcome the drug resistance.
